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DLC-1: a Rho GTPase-activating protein and tumour suppressor
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Abstract
The deleted in liver cancer 1 (DLC-1) gene encodes a GTPase activating protein that acts as a negative reg-
ulator of the Rho family of small GTPases. Rho proteins transduce signals that influence cell morphology and
physiology, and their aberrant up-regulation is a key factor in the neoplastic process, including metastasis.
Since its discovery, compelling evidence has accumulated that demonstrates a role for DLC-1 as a bona fide
tumour suppressor gene in different types of human cancer. Loss of DLC-1 expression mediated by genetic
and epigenetic mechanisms has been associated with the development of many human cancers, and
restoration of DLC-1 expression inhibited the growth of tumour cells in vivo and in vitro. Two closely related
genes, DLC-2 and DLC-3, may also be tumour suppressors. This review presents the current status of
progress in understanding the biological functions of DLC-1 and its relatives and their roles in neoplasia.
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Introduction
Small GTPases of the Ras superfamily are critical
components of the signalling pathways that control
many aspects of cell behaviour. The members of the
Rho (ras homology) branch of the Ras family were
originally characterized as regulators of the actin
cytoskeleton, but have now been implicated in a wide
range of cellular processes, such as proliferation,
motility, morphogenesis, vesiscular trafficking and
gene expression [1–3]. Rho-GTPase activity is fre-
quently dysregulated in human cancers and may
contribute to the growth and invasiveness of tumour
cells [4, 5]. The human genome encodes 20-22 Rho
proteins, of which the best characterized are RhoA,
Rac1 and Cdc42 [6, 7].
In common with other Ras-like GTPases, Rho pro-
teins act as molecular switches that undergo a
nucleotide-regulated conformational change. In the
GTP-bound state they transmit signals by activating
downstream effector molecules, such as protein and
lipid kinases, phospholipases and regulators of
cytoskeletal organization [1, 3]. The Rho GTP-GDP
cycle is controlled by two classes of regulatory pro-
teins; guanine nucleotide exchange factors (GEFs)
promote the exchange of bound GDP for GTP to
generate the active state, and GTPase activating
proteins (GAPs) stimulate GTP hydrolysis to recon-
stitute the inactive state [8].
In human beings, the ~~70 RhoGEFs and ~~80
RhoGAPs are structurally diverse multi-domain pro-
teins, and their activities are regulated and targeted
by interactions with other molecules [9–12]. A num-
ber of RhoGEFs are activated in response to stimu-
lation of cell surface receptors, and several GEFs
have been localized to complexes organized by scaf-
folding proteins that include downstream Rho effec-
tors, which would increase the efficiency and speci-
ficity of Rho signalling [13,14]. While fewer details are
known about RhoGAP signalling pathways, their
importance in normal cellular homeostasis is evi-
denced by the association of several human disor-
ders with mutations in RhoGAP genes and by the
abnormal phenotypes generated by targeted inacti-
vation of mouse RhoGAP genes [12,15]. One
RhoGAP that is rapidly gaining recognition for its role
as a tumour suppressor and a regulator of cell prolif-
eration and cytoskeletal organization is DLC-1 (delet-
ed in liver cancer 1). In this review we summarize the
current state of knowledge of DLC-1 and its relatives.
The deleted in liver cancer family of
RhoGAP domain proteins
The DLC-1 gene was identified by Yuan and col-
leagues as a genomic DNA segment under-represent-
ed in a human hepatocellular carcinoma (HCC) speci-
men, using representational difference analysis, a
PCR-based subtractive hybridization technique [16].
The DLC-1 locus was mapped to the human chromo-
some 8p22 region frequently lost in HCC and other
cancers (Fig. 1A), and it was named 'deleted in liver
cancer' when found to be deleted in primary HCC and
HCC cell lines [16]. Sequencing of the DLC-1 cDNA
showed that it was the human orthologue of the rat
p122RhoGAP protein, which had been cloned by
Homma and Emori when screening a gt11 expres-
sion library with anti-serum against phospholipase C
1 (PLC 1) [17]. The predicted amino acid sequence
of p122RhoGAP/DLC-1 contains a RhoGAP domain, a
conserved region of around 200 amino acids responsi-
ble for the catalytic activity of RhoGAPs [10]. Further
analysis of the DLC-1 polypeptide sequence revealed
the presence of two additional conserved elements, an
N-terminal sterile alpha motif (SAM) domain and a C-
terminal steroidogenic acute regulatory protein (StAR)-
related lipid-transfer (START) domain [18].
DLC-1 was later recognized as the founding member
of a family of proteins that shares the SAM-RhoGAP-
START domain organization, which now includes DLC-
2 (also known as STARD13, for START domain-con-
taining protein 13) [19, 20] and DLC-3 (also known as
KIAA0189 and STARD8) [21, 22] (Fig. 2). The genes
encoding the three human DLC proteins appear to be
paralogues that arose through duplication of chromoso-
mal segments [22]. Orthologues of each of the three
DLC family proteins have been found in other verte-
brates, including the mouse, rat, dog, chicken, frog and
puffer fish (Ensembl Project; http://www.ensembl.org).
The urochordate Ciona intestinalis and invertebrates
such as Drosophila and C. elegans appear to possess
a single gene encoding a DLC-1-like protein (Ensembl
Project). The SAM-RhoGAP-START domain proteins
apparently arose in multi-cellular organisms, as none of
the 11 predicted RhoGAP domain proteins in S. cere-
visiae is homologous to DLC-1 [23].
DLC-1
The human DLC1 gene is organized into 14 exons
and yields a major transcript with a size of ~~6.3 kb
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[24]. The longest open reading frame of the cDNA
(NM_006094) encodes a 1091-amino acid (aa)
polypeptide with a predicted size of 123 kD [16].
However, translation initiation at an in-frame, down-
stream AUG codon in a better Kozak context would
yield a protein of 1083 aa, and there is evidence that
the second AUG is the predominant start site (A.
Papageorge, X. Qian, D. Lowy, unpublished results).
The human DLC-1 aa sequence is 93% identical to
the rat p122RhoGAP [17] and 92% identical to 
the mouse protein [24, 25]. The rat Dlc1 gene on
chromosome 16q12.2 (Rat Genome Database;
http://rgd.mcwu.edu) and the mouse Dlc1 gene (for-
merly called Arhgap7 ) on chromosome 8B1  are
located on regions syntenic with human 8p22 and
have exon/intron structures nearly identical to that of
the human gene, except for the presence of an extra
codon in exon 5 of the mouse gene [24, 25].
Several variant transcripts are associated with the
DLC1 locus (Table 1 and Fig. 3A). The 7.4 kb
KIAA1723 cDNA clone was isolated from a human
hippocampus library and has the potential to encode
a larger DLC-1 isoform of 1528 aa [26]. The
KIAA1723 cDNA contains exons 2–14 of DLC1, 
but exon 1 is replaced by a novel 1.7 kb sequence,
distributed on 5 exons upstream of the start of the
Fig. 1 Tumour suppressor activity of DLC1. (A) The human DLC-1 gene is located in band 8p22, a chromosomal region of DNA
copy-number losses in a number of cancers, as demonstrated by conventional (left) and array-based (right) comparative genom-
ic hybridization. Re-expression of the DLC-1 cDNA in human tumour cells that lack expression of the endogenous gene results
in suppression of colony formation (B), suppression of cell invasion (C), reduction of actin stress fibres (D), diminution of vin-
culin-containing focal adhesions (E), reduction of tumour size in nude mice (F), induction of apoptosis (as demonstrated by cell
accumulation of sub-G1 phase and chromatin fragmentation) (G), and suppression of formation of lung metastases in nude mice
(H). In each pair of photographs, DLC-1-expressing cells are below (C, D, E, H) or to the right (B, F) of cells transfected with
control vectors. Images in H are reproduced with permission from Cancer Research.
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major transcript. The putative promoter region of
KIAA1723 is approx. 400 kb upstream of exon 2, and
there are also shorter transcripts originating from this
promoter that would not encode a DLC-1-related pro-
tein (NM_024767). The existence of a larger DLC-1
polypeptide has not yet been verified experimentally.
The second alternative transcript contains a novel
first exon located 160 kb upstream of exon 2 and was
cloned from HepG2 hepatoblastoma cells, where it
seems to be enriched, based on the number of pro-
moter tags in the Fantom database isolated from
these cells (http://fantom.gsc.riken.go.jp). The
HepG2-enriched first exon would substitute 47 aa for
the first 13 aa of DLC-1. As a transcript with a similar
5' end was identified in the mouse, this DLC-1 iso-
form may be functionally conserved.
DLC-2
DLC-2 was identified by analysis of genomic and
cDNA sequences as a gene on chromosome 13q13
that encoded a RhoGAP domain protein related to
DLC-1 [19, 20].The full-length DLC-2 cDNA is 6 kb,
and on Northern blots an additional 4 kb transcript
Fig. 2 Comparison of the mammalian and Drosophila DLC family proteins. Schematic representation of the structure of human
DLC-1, DLC-2 and DLC-3, the rat DLC-1 orthologue p122RhoGAP and Drosophila RhoGAP88C (cv-c). The SAM, serine-rich
(SR), RhoGAP and START domains are indicated. The amino acid length of the polypeptide is given at the right. Beneath each
domain is the percent identity to the corresponding domain of human DLC-1, and in parenthesis is the percent identity of the
full-length polypeptide.
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was detected in some tissues [19], possibly due to
alternative polyadenylation site usage. The DLC-2
gene (STARD13) also appears to have more than
one transcription start site, potentially yielding three
DLC-2 isoforms with different 5'-untranslated regions
and different N-termini (Fig. 3B). The DLC-2 tran-
script encodes an 1113-aa polypeptide of 125 kb that
is 58% identical to DLC-1 and has the same SAM-
RhoGAP-START domain organization [19].The DLC-
2 transcript contains a different first exon and
encodes an 1105 aa polypeptide, in which 46 aa
replace the first 56 aa of the  form [27]. In the third
transcript, DLC-2, translation is predicted to initiate
at an AUG codon equivalent to aa 119 of DLC-2,
yielding a 995-aa protein missing the SAM domain.
The biological significance, the relative abundance
and the tissue distribution of the three DLC-2 
isoforms remain to be determined. The mouse
Stard13 gene maps to chromosome 5G3, and 
full-length mouse cDNAs have been identified 
that encode a protein 90% identical the human 
DLC-2 isoform.
Isoform cDNA sequence (GenBank #) Protein Size (Amino acids) Protein Sequence (UniProt #)
DLC-1
Human NM_006094 1091 Q96QB1
Mouse NM_015802 1092 Q9R0Z9
Rat D31962 1083 Q63744†
DLC-1 long variant (KIAA1723)
Human NM_182643 1528 Q7Z5R8
DLC-1 variant (HepG2)
Human AK025544 1125‡ na
Mouse AK147539 1126 Q3UH75
DLC-2
Human NM_178006 1113 Q9Y3M8-1
Mouse NM_146258 1113 Q923Q2
DLC-2
Human NM_178007 1105 Q9Y3M8-2
DLC-2
Human NM_052851 995 Q9Y3M8-3
DLC-3
Human CR749411 1103 Q68DG7
Mouse BB613875§ 1099 na
DLC-3
Human NM_014725 1023 Q92502
Mouse NM_199018 1019 Q8K031
Table 1 Human and rodent DLC family members
na, not available.
† The 1083-aa protein described in [17] originates from the downstream AUG codon, and the 1091-aa protein in Q63744 derives
from the upstream AUG codon.
‡ The AK025544 nt sequence contains a sequencing error in the region shared with NM_006094 that would lead to premature
translation termination. The predicted polypeptide length was obtained from the corrected sequence.
§ This partial cDNA sequence contains a 5’ end similar to that of CR749411.
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DLC-3
The KIAA0189 cDNA clone was isolated from a
human myeloid cell line library and noted to encode
a protein related to p122RhoGAP [21]. Due to its
homology with DLC-1 and-2, we have now termed
this protein DLC-3. The gene encoding DLC-3
(STARD8) is present on chromosome Xq13, and the
organization of exons 2–14 of STARD8 is similar to
that of DLC1 and STARD13 [22]. The DLC-3 mRNA
has a size of  5 kb, and the gene appears to have
two transcription start sites that would produce
polypeptides with different N-termini. A transcript
originating from a distal promoter encodes the 122-
kDa DLC-3 isoform, an 1103-aa polypeptide con-
taining the SAM, RhoGAP and START domains that
is 44% identical to DLC-1 and 52% identical to DLC-
2 [22]. The original KIAA0189 cDNA apparently initi-
ates from a proximal promoter and encodes the
Fig. 3 Origin of human DLC-1 and DLC-2 transcriptional variants. (A). Diagram of the genomic region at the 5’ end of DLC1,
with exons represented by boxes. The five exons comprising the novel 5’ sequence of the KIAA1723 transcript are labelled A–E,
and the alternative first exon of the AK025544 transcript is denoted as 1*. The three transcripts share exons 2–14, and the dis-
tances between the putative transcription start sites (marked with arrows) and exon 2 are indicated. (B). Diagram of the 5’ end
of the DLC-2 gene, showing the first exons of the DLC-2 (1), DLC-2 (1) and DLC-2 (1) isoforms. Exons 2–14 are com-
mon to all three transcripts, and the distances between exon 2 and the putative transcription start sites are indicated. The
genomic DNA distances in A and B were obtained from the human genome sequence compilation (NCBI Build 36) and are not
drawn to scale. The structures of the human DLC-3 gene and its transcripts were described in Ref 22.
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DLC-3 isoform, predicted to encode a 1023-aa pro-
tein that lacks the SAM domain. As with the DLC-2
isoforms, there is a lack of information concerning
the nature of the endogenous DLC-3 protein. The
mouse Stard8 gene is found on chromosome XC2,
and there are mouse transcripts corresponding to
both the DLC-3 and  variants [22].
Invertebrate DLC-1-like proteins
In the Drosophila genome sequence there is a single
DLC-1-like protein, RhoGAP88C, encoded by the
gene crossveinless-c (cv-c) [11, 28]. The 1017-aa
RhoGAP88C polypeptide has the characteristic SAM
-GAP-START domain organization and has 40%
identity with DLC-1 and DLC-2 and 36% identity with
DLC-3.The C. elegans DLC-1 orthologue is the prod-
uct of the gene gei-1 (gut on exterior-interacting)
[29]. There are two gei-1 transcripts (F45H7.2a 
and F45H7.2b) that encode hypothetical proteins 
of 842 and 722 aa, respectively (WormBase;
http://www.wormbase.org). Both of the predicted
gene products lack the SAM domain; however, fur-
ther characterization of the 5' ends of the gei-1 tran-
scripts will be needed to confirm the absence of a
SAM domain. The 842-aa protein is slightly more
similar to DLC-2 (33% identity) than to DLC-1 or
DLC-3 (30% identity).
Expression of DLC family proteins
DLC-1 mRNA is widely expressed in human and
mouse tissues, as shown by Northern blot hybridiza-
tion [16, 24, 30] and by the large number of
expressed sequence tags (ESTs) isolated from many
tissues and at various stages of development
(http://www.ncbi.nlm.nih.gov, unigene database). By
in situ hybridization, the DLC-1 transcript was detect-
ed in several tissues in 10-day mouse embryos [31].
The transcription start sites of the human and mouse
DLC-1 genes have been identified, and the promoter
regions of both genes are GC-rich with characteris-
tics of CpG islands [24, 32–34]. Genomic DNA
upstream of the translation start site was found to
stimulate transcription of a luciferase reporter gene
in several human cancer cell lines [34]. DLC-1
expression could also be subject to control at the
post-transcriptional level, as the 5'-untranslated
region of the human, mouse, and rat transcripts have
upstream AUG codons, which might inhibit initiation
of translation at the start codon of the major open
reading frame [24]. The distribution of the DLC-2 and
DLC-3 mRNAs appears to overlap with that of DLC-
1 in many adult tissues [19, 21, 22]. Fewer ESTs
have been obtained for DLC-3, suggesting that it may
be synthesized by a more limited number of cell
types or that the transcript is present at lower levels.
Features of 
DLC family protein domains
SAM domain
The N-terminus of the DLC-1 polypeptide contains a
SAM domain (aa 11–78), an 70 amino acid motif
that occurs in more than 200 human proteins, includ-
ing transcription factors and signalling proteins [35].
Most SAM domains are thought to be involved in pro-
tein–protein interactions, although certain SAM mod-
ules have been reported to bind RNA and lipids [35].
Some SAM domain proteins interact with other SAM
domains in a homo- or heterotypic fashion to form
oligomers or multi-protein complexes, respectively.
Recent data indicated that the SAM domains of the
DLC family proteins may have unique features.
Determination of the  3D structure of the SAM domain
of DLC-2 showed that it formed a four- helical bundle,
instead of the usual five helices typical of other SAM
domains [36, 37]. The DLC-2 SAM domain was found
to exist in solution as a monomer and may interact
with a lipid ligand [36, 37] The absence of a SAM
domain in the DLC-2 and DLC-3 isoforms could
alter their biological properties; consistent with this
possibility, HCC cells could be stably transfected with
vectors encoding DLC-2 but not DLC-2 [27].
RhoGAP domain
Residues 639-847 of DLC-1 comprise the RhoGAP
domain, which is the most highly conserved domain
among the three DLC family members, with around
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70% sequence identity. The intrinsic GTP hydrolysis
rates of Rho proteins are low, and GAP domains
enhance their GTPase activity by positioning the cat-
alytic glutamine residue in the proper conformation for
aligning the nucleophilic water molecule that attacks
the -phosphate of GTP [8]. All of the DLC proteins
have a conserved arginine residue that is essential for
RhoGAP activity, corresponding to Arg677 of human
DLC-1. The 'arginine finger' is present in a loop and
introduces a positive charge into the catalytic site that
stabilizes the transition state of the GTP hydrolysis
reaction [38]. Rat p122RhoGAP and human DLC-1,
DLC-2 and DLC-3 were found to have GAP activity for
RhoA in vivo and in vitro [19, 39–41]. Human DLC-1
and DLC-2 have also been reported to increase the
hydrolysis of Cdc42-GTP in vitro, although less effi-
ciently than that of RhoA-GTP, and both had little
effect on the GTPase activity of Rac1 [22, 40].
START domain
The START domain at the C-terminus of DLC-1 (aa
878–1081) is a domain first identified in several proteins
with a role in lipid transport or lipid metabolism, and
subsequently START domains have been found in 15
human proteins [18, 42]. The 3D structures obtained
for several START domains show that they exist as a
hydrophobic tunnel formed by a curved, 9-stranded 
sheet gripped by N-terminal and C-terminal  helices
[42]. Different lipid-binding modules are found in other
RhoGAP proteins, such as the Sec14 domain in
Cdc42GAP and C1 domain in 2-chimaerin, and they
are thought to regulate the subcellular localization of
the protein and/or its GAP activity [10,43]. However, it
has been suggested that START domains may not be
involved in membrane targeting due to buried nature
of lipid-binding region [44]. Determination of the iden-
tity of the ligand(s) for the START domains of the DLC
family proteins will be essential for understanding the
function of this region.
Serine-rich, unstructured middle region
The region between the SAM and RhoGAP domains
of DLC-1 (aa 86-638), encoded primarily by the
unusually long exon 5 (1424 bp in humans), displays
little overall sequence similarity with known protein
domains. This region has the least sequence conser-
vation with DLC-2 and DLC-3, although alignment of
the sequences reveals short stretches of high similar-
ity separated by gaps and insertions of variable
length [22]. One of the conserved sequence elements
(LDDILYHV, residues 469–476 in human DLC-1) is
similar to the consensus LD motif (LDXLLXXL) found
in paxillin and other signalling proteins, which medi-
ates the binding of paxillin to vinculin and focal adhe-
sion kinase [45]. This middle region is rich in serine
residues, and computer analysis shows that there are
a number of potential sites for phosphorylation by ser-
ine-threonine protein kinases (ELM server,
http://elm.eu.org). There are also several proline-rich
segments in the serine-rich (SR) region that could
bind to proline recognition domains, such as the SH3
(src homology 3) and WW (Trp-Trp motif) modules
that are present in many signalling proteins [46].
Secondary structure analysis using the programs
FoldIndex (http://bioportal.weizmann.ac.il/fldbin/findex)
and PONDR (http://www.pondr.com) predicts that large
stretches of the SR region are not likely to adopt a glob-
ular conformation (Fig. 4). Instead, this domain has sev-
eral features in common with a class of proteins that
have been termed intrinsically unstructured (or disor-
dered) proteins [47, 48]. Unstructured protein domains
are characteristically enriched in amino acids that pro-
moter disorder (S, P, Q, E, K) and deficient in hydropho-
bic amino acids that form the core of globular proteins.
Compared to globular domains, unstructured domains
tend to have a lower degree of sequence conservation,
due to a faster rate of evolution. This category includes
many regulatory and signalling proteins, and their lack
of secondary structure has been recognized as an
important factor in the functions of these proteins. Their
open, extended conformation confers flexibility and the
ability to harbour multiple sites for interactions with other
molecules. The unfolded structure can also impart
increased susceptibility to proteolysis, providing a
means for regulated turnover of the protein.
Unstructured domains are also preferred sites for
post-translational modifications such as phosphory-
lation [47], which serves as a reversible means of
regulating the activity and/or subcellular localization
of many signalling proteins, including several
RhoGAPs [43]. This domain appears to be undergo
phosphorylation at multiple sites in the DLC family
proteins. Ser322 of rat p122RhoGAP (equivalent to
Ser329 in human DLC-1) was phosphorylated in rat
adipocytes after insulin treatment, and this was
blocked by wortmannin, a phosphatidylinositol 3-
kinase inhibitor [49]. Recombinant p122RhoGAP
was phosphorylated on Ser322 in vitro by protein
J. Cell. Mol. Med. Vol 11, No 5, 2007
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kinase B and ribosomal S6 kinase. A cluster of 7
phosphorylation sites in rat DLC-1, equivalent to
Ser304, Ser305, Ser310, Thr312, Ser313, Ser 317
and Thr318 in the human sequence, was found in a
large-scale characterization of phosphopeptides in
vasopressin-treated rat kidney cells [50]. A proteom-
ic analysis of phosphorylated peptides in mouse liver
identified Ser89 of DLC-1 and an equivalent residue
in DLC-2 (Ser133 in the human sequence) as phos-
phorylation sites [51]. An additional site was found 
in DLC-2 (corresponding to Ser572 in the human
protein), and the sequence surrounding Ser572
(RRDSGVGASLTR) is identical in DLC-1 and 
DLC-3 and is similar to the RRXS protein kinase 
A phosphorylation site consensus sequence 
[52]. Phosphorylation of these sites has not yet 
been shown to have an effect on the activities of
DLC-1 or DLC-2.
Fig. 4 Structural and functional features of the serine-rich domain of DLC-1. (A). Graphical representation of the predicted second-
ary structure of the human DLC-1 protein, performed using the FoldIndex program (http://bioportal.weizmann.ac.il/fldbin/findex).
The serine-rich region between the SAM and RhoGAP domains is predicted to have a largely unfolded conformation. (B). Features
of the serine-rich region. The amino acid sequence of the region between the SAM and RhoGAP domains (residues 79–638) of
human DLC-1 is shown, and residues that were found to be phosphorylated in the mouse [51] and rat [49,50] DLC-1 proteins are
indicated in yellow. Phosphorylation of Ser549 was presumed, since the equivalent serine in a highly conserved region of mouse
DLC-2 was phosphorylated [51]. The tensin-binding site (SIYDNV) and the LD motif (LDDILYHV) are shown in blue.
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Biological functions of DLC-1 
Cytoskeletal organization 
The assembly of actin filaments into various struc-
tures is initiated at sites of cell-cell and cell-extracel-
lular matrix contact and involves the formation of
large multi-protein complexes that include structural
and regulatory proteins [53]. These complexes are
dynamic structures, and their re-modelling coincides
with changes in morphology and cell movement dur-
ing development, and in adults with processes, such
as wound healing and tumour metastasis. The iden-
tification of p122RhoGAP as a regulator of RhoA
activity prompted studies of its effect on the forma-
tion of two RhoA-dependent structures: actin stress
fibres, long thick bundles of actin filaments associat-
ed with myosin, and focal adhesions, which are multi-
protein complexes at the end of stress fibres that pro-
vide a link between the actin cytoskeleton and the
integrin family of extracellular matrix receptors [54].
Over-expression of DLC-1/p122RhoGAP in cultured
cells resulted in a rounded morphology associated
with the disruption of actin stress fibres and focal
adhesions [39, 55, 56] (Fig 1D and E). Using overlap-
ping deletion mutants, the ability of DLC-1 to disrupt
the cytoskeleton was shown to require the presence
of the RhoGAP domain, and point mutations that
abolished GAP activity reduced this inhibitory effect
[39, 55, 56]. DLC-1 over-expression led to the de-
phosphorylation of the focal adhesion proteins FAK,
paxillin and Cas [56], pointing to a possible mecha-
nism by which DLC-1 may interfere with focal adhe-
sion formation. DLC-1 may have additional effects in
cells cultured on different substrata, as it was found
to promote the extension of long membrane protru-
sions in cells plated on laminin-1 [56].
DLC-1 localizes to focal adhesions via
binding to tensin family proteins
While DLC-1 ectopically expressed in cultured cells can
have a diffuse cytoplasmic localization [39, 55, 57], 
in certain cell types DLC-1 may be present in focal
adhesions. In normal rat kidney (NRK)  fibroblasts,
endogenous p122 RhoGAP/DLC-1 and a GFP-
tagged N-terminal fragment (aa 1-534) were detect-
ed in focal adhesions, as shown by their co-localiza-
tion with the tips of actin stress fibres and with vin-
culin, a focal adhesion protein [58]. Recently, yeast
two-hybrid screenings identified DLC-1 as a binding
partner for members of the tensin family of focal
adhesion proteins [41, 59, 60]. The four tensin pro-
teins (tensin1, tensin2, tensin3 and cten) bind to the
cytoplasmic tails of  integrins [61]. The middle
region of DLC1 was found to interact with the C-ter-
mini of the tensins, which consist of SH2 (src homol-
ogy 2) and phosphotyrosine-binding (PTB) domains
[41, 59, 60]. DLC-1 bound to the SH2 domains of
cten and tensin1, and the binding site was mapped
to aa 440–445 (SIYDNV) of DLC-1 [41, 60]. Mutation
of Tyr442 of DLC-1 abolished the SH2 domain bind-
ing, but phosphorylation of Tyr442 was not required
for the interaction, unlike most ligands for SH2
domains. [41, 60]. Binding of DLC-1 to the PTB
domains of tensin1 and tensin2 was also detected
[41, 59], and DLC-1 competed with integrin 3 for
binding to the tensin1 PTB domain [41]. Tensin and
DLC-1 co-localize (Fig. 5), and the localization of
ectopically expressed DLC-1 to focal adhesion-like
structures was dependent on the co-expression of
tensin proteins [41, 59, 60].
Interaction of DLC-1 with caveolin-1
Caveolin-1 is a 22 kD protein that is an essential
component of caveolae, plasma membrane domains
that appear as flask-shaped invaginations at the cell
surface and are enriched in cholesterol and sphin-
golipids [62]. Endogenous DLC-1 was found to sedi-
ment with caveolin-1 in low-density cholesterol-rich
membrane fractions [63], and both endogenous and
myc-tagged DLC-1 were co-immunoprecipitated with
caveolin-1 [59, 63]. Since multiple functions have
been proposed for caveolae [62, 64], and caveolin-1
has been found in membrane subdomains other than
caveolae, including focal adhesions [64, 65], the
physiological significance of the interaction between
DLC-1 and caveolin-1 requires further investigation.
DLC-1 and phosphoinositide signalling
The isolation of the rat p122RhoGAP cDNA by
screening an expression library with anti-serum
raised against PLC-1 suggested that the two pro-
teins can interact, and recombinant p122RhoGAP
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was found to bind PLC-1 and to stimulate the
hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2) by PLC-1 [17]. PIP2 hydrolysis generates two
second messengers, diacylglycerol, which activates
proteins with C1 domains, such as protein kinase C,
and inositol 1,4,5-trisphosphate, which promotes the
release of Ca2+ from internal stores to regulate calci-
um-responsive proteins [66]. p122RhoGAP did not
bind PLC-1 or PLC-1 [17], which are activated by
receptor-coupled heterotrimeric G proteins and
receptor tyrosine kinases, respectively [66]. The
PLC-1 binding activity of p122RhoGAP appeared to
reside in the C-terminal half of the polypeptide, as a
fragment consisting of aa 617-1083 promoted the
release of intracellular Ca2+ [39]. Whether DLC-2 and
DLC-3 also interact with PLC-1 has not been deter-
mined. In addition to serving as a precursor for other
lipid second messengers, PIP2 also has an impor-
tant role in regulating cytoskeleton assembly by
inducing conformational changes in actin-binding
proteins, such as vinculin and talin [67]. Thus DLC-1
could influence cytoskeletal dynamics by altering
local PIP2 levels as well as by regulating Rho
GTPase activity.
Biological activities of DLC-2 and DLC-3
Consistent with its similarity to DLC-1, over-expres-
sion of DLC-2 has been found to induce cell round-
ing and disrupt actin filaments in liver and breast can-
cer cells [20, 27], and this effect was eliminated by
mutation of critical residues in the RhoGAP domain
[27]. When recombinant DLC-2 was expressed at
lower levels to reduce cytotoxicity, the protein was
found to co-localize with mitochondrial markers,
using immunofluorescence and cell fractionation
[68]. DLC-2 was also detected in structures that
resembled lipid droplets, and targeting to mitochon-
dria and lipid droplets was mapped to the START
domain [68]. Recombinant DLC-2 was found to form
homodimers in solution, and residues 120–672 were
responsible for self-association [36]. It will be of inter-
est to determine whether dimerization is a property
of the other DLC family proteins. Studies on the bio-
logical functions of DLC-3 have just begun, but the
amino acid sequence contains a segment similar to
the DLC-1 tensin-binding site (STYDNL, aa
353–358) and full-length DLC-3 was shown to bind
the SH2 and PTB domains of tensin1 [41].
Genetic analysis of DLC-1 function
Mouse DLC-1 gene knockout
Evidence that DLC-1 has a crucial role in cytoskele-
tal organization and morphogenesis in vivo has
come from the discovery that null mutations in the
gene result in embryonic lethality in mice and flies.
We used gene targeting to disrupt the mouse DLC-1
Fig. 5 Co-localization of DLC-1 and tensin. Confocal photomicrographs showing endogenous tensin (red, A) and transfected GFP-
DLC1 fusion protein (green, B) in human fibroblasts. The merged image (C) shows co-localization of tensin and DLC-1 in focal
adhesions, indicated in yellow. The bar represents 10 µm. (Images courtesy of Dr. Guorong Li, Laboratory of Cellular Oncology,
National Cancer Institute).
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gene and found that DLC-1 was essential for viabili-
ty, as embryos homozygous for the mutated allele did
not survive beyond 10.5 days gestation [31].
Histological examination of 9.5-day DLC-1-/- embryos
revealed an open anterior neural tube, abnormalities
in the branchial arches, brain neuroepithelium and
heart, and defective foetal blood vessels in the pla-
cental labyrinth [31]. The related DLC-2 and DLC-3
gene products were apparently unable to compen-
sate for DLC-1 deficiency during development.
Fibroblasts from 9.5 day DLC-1-/-embryos were able
to proliferate in culture, but displayed a reduction in
actin stress fibres and vinculin-containing focal adhe-
sions, suggesting that loss of DLC-1 may have inter-
fered with development by adversely affecting the
assembly of the cytoskeleton and cell adhesion com-
plexes [31]. The phenotype of DLC-1-deficient
mouse embryo fibroblasts may seem inconsistent
with studies showing that over-expression of DLC-1
in cultured cells disrupts focal adhesions and actin
stress fibres [39, 55]. On one hand, the response of
primary cell cultures may differ from that of immortal-
ized cell lines that have accumulated genetic alter-
ations. However, the deleterious consequences of
both the absence and over-expression of DLC-1 may
signify that it serves as an adaptor or scaffolding pro-
tein that must be present at an optimal level to inter-
act with other components of a signalling complex.
Either a deficiency or an excess of a scaffolding pro-
tein can impair formation of the complex and reduce
signal propagation [69].
RhoGAP88C in Drosophila
The Drosophila DLC-1 orthologue RhoGAP88C was
found to be essential for viability in a study using
RNA interference to inactivate Drosophila RhoGAP
genes [70]. Phenotypic analysis of mutant alleles of
the cv-c gene encoding RhoGAP88C has provided
striking confirmation of the essential role of the DLC
proteins in actin cytoskeleton dynamics during mor-
phogenesis. Viable hypomorphic alleles of cv-c lead
to loss of the posterior crossvein and detachment of
the anterior crossvein in the wings of adult flies [28].
Molecular characterization of embryonic lethal alle-
les showed that two are apparently null alleles result-
ing from nonsense mutations, and a third (cv-c7) has
a missense mutation (Arg601Gln) that targets the
'arginine finger' of the RhoGAP domain. The lethal
alleles caused abnormalities in tissues undergoing
morphogenetic movements, including delayed dorsal
closure of the epidermis and defects in head involu-
tion, midgut constriction and Malpighian tubule elon-
gation. In Malpighian tubules, either RhoGAP88C
deficiency or over-expression resulted in actin
cytoskeleton disorganization. Genetic analysis of the
interactions between cv-c and several RhoGTPase
mutants indicated that RhoGAP88C regulated different
RhoGTPase substrates in a tissue-specific fashion [28].
Two recent studies indicated that cv-c is required
for the cell shape changes that take place during
epithelial invagination in Drosophila spiracle and tra-
chea morphogenesis. The apical constriction of the
invaginating cells of the trachea and the posterior
spiracle depended on the activation of Rho1 at the
apical membrane and the consequent apical accu-
mulation of F-actin and myosin II [71, 72]. In cv-c
mutants, the invagination defects in tracheal and
spiracle cells were associated with the abnormal
subcellular distribution of F-actin and myosin II [71, 72].
RhoGAP88C was present in the basolateral domain
of invaginating spiracle cells in normal embryos,
where it may down-regulate Rho activity and cooper-
ate with two apically localized RhoGEFs,
RhoGEF64C and RhoGEF2, in restricting Rho1 acti-
vation and actomyosin contraction to the apical sur-
face to generate cell shape changes during morpho-
genesis [72]. Expression of cv-c in the developing
trachea was reduced in mutants with defective EGF
signalling [71], thus placing the DLC family proteins
downstream of the EGF receptor in some tissues
during development.
No mutations in the C. elegans DLC-1 homologue
gei-1 have been reported, but there is indirect evi-
dence that it may also be involved in cytoskeletal
organization. By yeast two hybrid screening, the gei-1
gene product was identified as a protein that inter-
acts with gex-2 (gut on exterior 2) [29], a gene essen-
tial for normal morphogenesis in C. elegans that
encodes the nematode homologue of mammalian
Sra-1 (specifically Rac associated protein 1, also
known as PIR121) [73], a Rac1 effector and compo-
nent of the WAVE/Scar protein complex that regu-
lates branching actin filament assembly [53].
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The DLC family proteins in cancer
Decreased expression of DLC-1 in
human cancers
Rho GTPases are involved in the regulation of cellu-
lar processes, such as proliferation, motility and
apoptosis that are typically altered during oncogene-
sis [74]. Rho GTPase activity is increased in a variety
of human cancers, but this has not been associated
with the occurrence of activating mutations in Rho
protein genes, in contrast with Ras [5, 75]. Some
RhoGAPs could potentially serve as tumour sup-
pressors, if their loss resulted in a dysregulation of
Rho protein activity that facilitated the growth and
metastasis of cancer cells. Considerable evidence
has accumulated that DLC-1 can act as a tumour
suppressor in a wide spectrum of human cancers.
While DLC-1 mRNA is expressed in many adult
human tissues, it is down-regulated or absent in a
number of common human cancers, including HCC
[16, 40, 76], breast [77–79] colon [79], ovarian [79, 80],
uterine [79], gastric [33], lung [79, 81–83], pancreat-
ic [84], prostate [85], renal [79] and nasopharyngeal
tumours [86]. Reduced mRNA levels have also been
found in non-malignant conditions, such as uterine
fibroids [87] and benign prostatic hyperplasia [85].
There had been little data on the relative abundance
of the DLC-1 protein in normal and neoplastic tis-
sues, but recently decreased DLC-1 protein levels
were reported in prostate tumour samples compared
to normal prostate tissue [85].
Deletions of DLC1 in tumours
The 8p22 region-containing DLC1 is commonly
under-represented in a variety of solid tumours and
haematological malignancies [88], and deletions at
the DLC1 locus were detected in HCC cell lines and
primary HCC using Southern blot hybridization and
loss of heterozygosity (LOH) analysis [16, 40, 76].
Subsequently DLC1 copy number losses were found
in other common human cancers, including breast
[77, 89], lung [81], nasopharyngeal [86] and prostate
cancer [85]. Although the 8p21–22 regions does not
correspond to a fragile site (FS), its propensity for
deletion is similar to that of the most unstable and
vulnerable FSs [90, 91]. The proximity of DLC1 to a
break in the mouse/human synteny [24] could predis-
pose it to deletions, since these evolutionary break-
points often coincide with regions of instability in
tumours [92].
Epigenetic inactivation of DLC-1
expression
Epigenetic mechanisms also lead to silencing of
tumour suppressor genes, and hypermethylation of
cytosine bases within CpG dinucleotides in GC-rich
promoter regions is the best characterized chromatin
modification associated with transcriptional repres-
sion in human malignancies [93]. The first evidence
implicating aberrant promoter methylation in the
down-regulation of the DLC-1 gene was obtained by
screening several cell lines derived from HCC,
breast, colon and prostate tumours [32]. Subsequent
analyses showed that promoter methylation is the
principal mechanism responsible for inactivation of
the DLC-1 gene in a number of solid tumours (Table 2).
Hypermethylation of the DLC-1 promoter may be an
early event in the development of prostate neo-
plasms, as it was also observed in a majority of
benign prostatic hyperplasia cases [85]. Aberrant
DLC1 methylation has been detected in several
haematological malignancies (Table 3), which is of
interest, since DLC-1 mRNA levels are low in normal
peripheral blood leucocytes but can be detected in
lymph node, thymus and spleen [22, 97], suggesting
that DLC-1 may be expressed at certain stages of
lymphocyte development. The relative ease of PCR-
based techniques for detecting methylation may
make DLC1 promoter hypermethylation a useful bio-
marker for diagnosis, staging, prediction and moni-
toring for recurrence of certain malignancies.
Reactivation of DLC-1 expression in cancer cell lines
with promoter hypermethylation can be achieved in
some cases by treatment with the DNA methyltrans-
ferase inhibitor 5-aza-2'-deoxycytidine [32, 33, 40, 85,
94–96, 98].
Alterations in histone modifications also occur in
cancer and may contribute to silencing of DLC-1.
Transcriptional repression has been linked with his-
tone hypoacetylation, which is promoted by the
recruitment of histone deacetylases to chromatin [99].
DLC-1 expression was increased after treatment with
the histone deacetylase inhibitor trichostatin A (TSA)
in several human gastric cancer [33], prostate cancer
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[85], multiple myeloma [96] and leukaemia [98] cell
lines. In some cell lines DLC-1 was not induced by
TSA unless the cells were co-treated with 5-aza-2'-
deoxycytidine [33, 97, 98]. Since epigenetic changes
are potentially reversible, compounds that reactivate
tumour suppressor genes silenced by DNA methyla-
tion or histone de-acetylation may be useful anti-can-
cer agents. Drugs that bring about DNA de-methyla-
tion or histone acetylation have shown promise in
clinical trials, and combination therapy with inhibitors
of both processes is under investigation [100].
Cancer-associated epigenetic changes may have
their origin in transcriptional mechanisms that control
developmentally regulated genes. The Polycomb
group (PcG) of transcriptional repressors help to
maintain the multi-potent state of stem cells by
reversibly repressing genes involved in differentiation
and inhibition of cell proliferation [101]. Recently
DLC1 and several other genes silenced by methyla-
tion in cancer were found to be targets of PcG pro-
teins in human embryonic fibroblasts [102] and
human embryonic stem cells [103]. PcG binding to
Table 2 Methylation of the DLC1 promoter region in human cancers: solid tumours
Tumour type Fraction of samples methylated Percent methylated Reference
Primary hepatocellular carcinomas 6/25 24 [40]
Hepatocellular carcinoma cell lines 3/7 43 [40]
Non-small cell carcinoma cell lines 10/19 53 [81]
Non-small cell carcinomas 11/18 61 [82]
Matching normal tissue 2/8 25 [82]
Non-small cell carcinoma cell lines 2/11 18 [82]
Gastric carcinomas 29/97 30 [33]
Gastric cancer cell lines 5/7 71 [33]
Prostate carcinomas 13/27 48 [85]
Matching normal tissue 2/27 7 [85]
Benign prostate hyperplasia 15/21 71 [85]
Normal prostate tissue 0/10 0 [85]
Breast carcinomas 5/14 36 [34]
Breast carcinoma cell lines 3/9 33 [34]
Breast carcinomas 4/39 10 [94]
Breast carcinoma cell lines 5/20 25 [94]
Nasopharyngeal carcinomas 31/39 79 [86]
Nasopharyngeal carcinomas 64/72 89 [34]
Nasopharyngeal carcinoma cell lines 11/12 91 [34]
Oesophageal carcinomas 48/94 51 [34]
Oesophageal carcinoma cell lines 6/15 40 [34]
Cervical carcinomas 7/8 87 [34]
Cervical carcinoma cell lines 5/8 63 [34]
Renal cell carcinomas 12/34 35 [95]
Matching normal tissue 1/34 3 [95]
Renal carcinoma cell lines 1/7 14 [95]
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tumour suppressor genes, such as DLC1 may be a
mark that predisposes them to persistent silencing
during the development of neoplasia by aberrant
recruitment of DNA methyl transferases [102, 104].
DLC-1 sequence variants in human
cancers 
Mutational analysis of the DLC-1 gene in tumour DNA
samples revealed that somatic mutations in the cod-
ing region are uncommon in HCC [76, 105] and col-
orectal [30], ovarian [30], brain [106], head and neck
[107] and prostate cancers [108]. A number of single
nucleotide polymorphisms (SNPs) have been identi-
fied in the DLC-1 genomic DNA sequence that could
be used for determining whether DLC-1 variants are
associated with altered susceptibility to cancer or
other human disorders. A familial prostate cancer
susceptibility gene was mapped near the DLC-1
locus on 8p22 [109], but a mutation screening and
association study did not reveal significant differences
in the DLC1 SNP frequencies in prostate cancer
cases and controls [108]. However, in a large-scale
genomic screen, DLC1 was identified as a highly sig-
nificant breast cancer susceptibility gene [110,111].
DLC-1 suppresses tumour cell growth
Evidence that DLC-1 can inhibit the growth of tumour
cells has come from experiments in which the cDNA
was transfected into human cancer cell lines that do
not express the endogenous gene. Restoration of
DLC-1 expression inhibited cell proliferation and
colony formation in HCC [55–57, 76] and in breast
[77, 89], lung [41, 81, 83], nasopharyngeal [34],
oesophageal  [34] and epithelial ovarian cancer cells
[112] (Fig. 1B). DLC-1-mediated inhibition of HCC
and ovarian cancer cell proliferation was associated
with the induction of apoptosis (Fig. 1G), marked by
the cleavage of procaspase-3 [57, 112]. DLC-1
expression reduced anchorage-independent growth
of HCC [55], ovarian cancer [112] and lung cancer
[41] cells in soft agar colony forming assays, an in
vitro measure of tumourigenicity. Over-expression of
DLC-1 was also able to suppress the growth of
tumours in athymic nude mouse xenograft models.
Tumour formation was abolished in DLC-1-transfect-
ed human breast cancer cells [89] and non-small cell
lung cancer cells [81], and the size of tumours was
reduced in HCC cells [55, 57] (Fig. 1F). Inhibition of
tumour cell growth by DLC-1 has been attributed to
its ability to down-regulate Rho protein activity, as
RhoGAP-deficient mutants were less active in sup-
pressing cell growth [41, 55]. Mutation of the tensin-
binding site also reduced growth inhibition by DLC-1
[41, 60], without affecting its overall RhoGAP activity
in vivo [41], indicating that either the tumour suppres-
sor function of DLC-1 may require targeting of the
RhoGAP activity by tensin or that DLC-1 has addi-
tional functions that do not involve the GAP domain.
DLC-1 as a metastasis suppressor gene
Losses at chromosome 8p have been linked to
increased metastasis, poorer prognosis and higher
tumour grade in several human cancers [113], and the
DLC-1 gene at 8p22 has been implicated in the
metastatic process. DLC-1 was found to be consistent-
ly down-regulated in highly invasive HCC cell lines and
Table 3 Methylation of the DLC1 promoter region in human cancers: Haematological malignancies
Cancer type Fraction of Samples methylated Percent methylated Reference
Multiple myeloma 11/14 78 [96]
Normal bone marrow 0/4 0 [96]
Multiple myeloma cell lines 3/4 75 [96]
Non-Hodgkin’s lymphoma 65/75 87 [97]
Normal lymphocytes 0/5 0 [97]
Non-Hodgkin’s lymphoma cell lines 6/6 100 [97]
Acute lymphoblastic leukaemia 14/16 88 [98]
Leukaemia cell lines 3/4 75 [98]
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metastatic subclones compared to non-metastatic
ones [114]. In assays using cultured cells, re-expres-
sion of DLC-1 inhibited the motility and invasiveness of
HCC [55–57] (Fig. 1C), breast cancer [115], ovarian
cancer [112] and lung cancer cell lines [41]. Both the
RhoGAP and tensin-binding activities have been
implicated in the inhibition of migration [41].
Transcriptional profiling of two subclones of the MDA-
MB-435 cell line showed that DLC-1 was one of the
genes down-regulated in metastatic M4A4 cells rela-
tive to non-metastatic NM2C5 cells [115]. Restoration
of DLC-1 expression in M4A4 cells to the levels
observed in the non-metastatic cells decreased the
size and abundance of pulmonary metastases formed
in nude mice [115] (Fig. 1H). In another metastasis
model system, DLC-1 expression was reduced in
human MDA-MB-231 breast cancer cells that had
been selected for increased metastasis to bone [116].
Lower DLC-1 levels in primary tumours could serve as
a marker for those with a greater potential for metas-
tasis and a worse prognosis. Gene expression profil-
ing analyses have found that DLC-1 expression was
higher in doxorubicin-sensitive breast tumours com-
pared to doxorubicin-resistant ones [117], and down-
regulation of DLC-1 was associated with reduced sur-
vival of patients with high-grade gliomas [118] and of
hepatitis C virus-positive HCC patients awaiting liver
transplantation [119]. Microarray studies have also
shown that DLC-1 expression can be used to distin-
guish lymphoma and leukaemia subtypes with differ-
ent clinical behaviours [120,121].
Regulation of DLC-1 by anti-oncogenic
factors
Several studies using microarray gene expression
profiling have shown that DLC-1 expression was up-
regulated in cultured cells after treatment with agents
that inhibit cell proliferation and/or promote differenti-
ation. DLC-1 mRNA levels were increased in HT-29
colon cancer cells treated with flavone, a dietary
flavonoid that inhibits growth and induces apoptosis
[122]. A recent study confirmed that flavone caused
a nearly fivefold increase in the amount of DLC-1
mRNA in HT-29 colon cancer cells and also found
that flavone treatment induces DLC-1 expression in
several human breast cancer cell lines [123]. DLC-1
levels were increased in cultured Wilm's tumour cells
treated with all-trans retinoic acid [124], a vitamin A
metabolite well-known for stimulating differentiation
and suppressing carcinogenesis [125]. DLC-1 was
one of the genes up-regulated in ovarian cancer cells
treated with high concentrations of progesterone that
inhibited cell growth [112]. Activators of the peroxi-
some proliferator-activated receptor  (PPAR), a
member of the steroid hormone receptor family of
transcription factors, promote differentiation and
inhibit the growth of several epithelial types of cancer
[126]. Over-expression of PPAR in lung cancer cells
decreased invasivesness and tumourigenesis and
induced expression of DLC-1 [127]. Further 
investigations may reveal how DLC-1 contributes to
the phenotype of cells treated with anti-oncogenic
compounds.
Animal models of DLC-1 in cancer
The embryonic lethality of the DLC-1-/- mice preclud-
ed attempts to investigate the effect of constitutive
DLC-1 deficiency on tumour development. The het-
erozygous animals were phenotypically normal
despite lower levels of DLC-1 mRNA, and they did
not have an increased incidence of spontaneous
tumour formation [31], suggesting that haploinsuffi-
ciency of Dlc1 was unable to initiate neoplastic devel-
opment. Alternative technologies may be needed to
generate tissue-specific inactivation of the gene to
study the effect on neoplasia in various organs. The
rat may also be a promising model for studying DLC-
1 in tumourigenesis. The CpG island at the 5' end of
the Dlc1 gene was found to be hypermethylated in rat
liver tumour cell lines that did not express DLC-1
RNA [128]. A gastric cancer resistance locus (Gcr3)
that reduced the size and depth of invasion of N-
methyl-N’-nitro-N-nitrosoguanidine-induced stomach
carcinomas was mapped to the vicinity of the Dlc1
gene on rat chromosome 16q [129].
Evidence for roles of DLC-2 and DLC-3
in neoplasia
In addition to their structural and functional similari-
ties with DLC-1, the other two human DLC family
genes may also be involved in oncogenesis. The
STARD13/DLC2 locus at chromosome 13q13 is
another frequent target of genomic DNA deletions in
several human cancers [88]. LOH at the 13q13 locus
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and under-expression of DLC-2 were observed in
primary HCC tissues [19]. Down-regulation of DLC-2
mRNA was also detected in a significant fraction of
primary lung, ovary, kidney, breast and uterine
tumours [79]. The GAP domain of DLC-2 was able to
suppress Ras signalling and inhibit the transforma-
tion of NIH3T3 cells when co-transfected with onco-
genic Ras [19]. DLC-2 over-expression was found to
inhibit the growth of MCF-7 breast cancer cells [20].
Transfection of the DLC-2 isoform into the HepG2
cell line decreased proliferation, RhoA activity, motil-
ity and the ability to form colonies in soft agar [27].
The STARD8/DLC3 locus on chromosome Xq13 is
near a site of LOH in ovarian cancers [130], but this
region has not been reported to be frequently delet-
ed in other cancer types [131]. Reduced DLC-3
mRNA levels were observed in a majority of human
prostate, kidney, lung, breast, uterine and ovarian
cancer tissues analysed [22]. Over-expression of
DLC-3 inhibited the proliferation, colony forming abil-
ity, and anchorage-independent growth of human
breast and prostate cancer cell lines [22]. In a large-
scale analysis of mutations in human breast and
colon cancers, two missense mutations in
STARD8/DLC3 were found in breast tumours [132].
Whether these alterations, both located in the SR
region (Gly268Ser and Glu322Lys, in the DLC-3
amino acid sequence), have an effect on DLC-3
activity remains to be determined.
Conclusions and future directions
Both in vitro and in vivo studies have provided firm
evidence that DLC-1 has a role in regulating actin
cytoskeleton organization. The Drosophila DLC-1
orthologue participates in localizing Rho GTPase
activity to sites undergoing cytoskeleton rearrange-
ments during morphogenesis.The RhoGAP activity of
DLC-1 may be targeted to particular subcellular
domains by binding to the tensins and other mole-
cules. Further efforts using mass-spectrometry-based
proteomic analyses and yeast two-hybrid screening
will reveal additional interaction partners of DLC-1
and help to elucidate its role in the signalling path-
ways that regulate cell adhesion, migration and prolif-
eration. This knowledge will also aid in understanding
how the loss of DLC-1 in neoplasia contributes to
tumour cell growth and metastasis. More information
is required on the mechanisms responsible for regu-
lating DLC-1 at various levels, including transcription,
translation, and post-translational processes, such as
phosphorylation and proteolytic degradation.
Determining the biological functions specific to each
of the DLC proteins will shed light on the raison d'être
for having three DLC genes in vertebrates.
The anti-cancer properties of DLC-1 may have
clinical applications. Since cells derived from differ-
ent types of cancer are highly sensitive to re-expres-
sion of DLC-1, the potential for effective therapy
based on DLC-1 transfer appears high. Screening for
dietary and pharmacological agents that up-regulate
DLC-1 gene expression could lead to the develop-
ment of drugs that might be useful for chemopreven-
tion and therapy. Identification of the pathways in
which DLC-1 operates may aid in the screening or
design of small molecules that can mimic the effects
of DLC-1 and inhibit tumour progression.
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